Literature DB >> 10746799

Pathophysiology of renal anemia.

K U Eckardt1.   

Abstract

Normochromic normocytic anemia regularly develops in chronic renal failure when the glomerular filtration rate drops below 20-30 ml/min. The reasons include: 1) a moderately reduced red cell life span, 2) blood loss, and 3) an inadequate increase in erythropoiesis relative to the fall in hemoglobin (Hb). The life-span of red blood cells may be shortened by their reduced resistance to mechanical, osmotic or oxidative stress, as well as by extracorpuscular factors. Blood loss results from dialysis, diagnostic sampling and, in particular, occult gastrointestinal bleeding. The predominant cause of inadequate erythropoiesis is a failure to increase erythropoietin (EPO) production in response to the developing anemia. Experience with recombinant EPO has shown that relative EPO deficiency is the key cause of the anemia and that the response of hematopoietic progenitor cells is not usually diminished in renal failure. However, reduced iron availability, inadequate dialysis, infection and hyperparathyroidism can all impair the efficacy of EPO. Therapeutic use of EPO has also shown clearly for the first time that anemia is responsible for a significant proportion of morbidity in patients with chronic renal failure and probably also contributes to increased mortality through its cardiovascular complications.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10746799

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  9 in total

1.  Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents.

Authors:  M R Silver; R Geronemus; M Krause; C Y Chen; R Kewalramani; C Stehman-Breen
Journal:  Curr Med Res Opin       Date:  2009-01       Impact factor: 2.580

2.  A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study.

Authors:  Loreto Gesualdo; Gérard London; Matthew Turner; Christopher Lee; Karen Macdonald; David Goldsmith; Adrian Covic; Philippe Zaoui; Christian Combe; Johannes Mann; Frank Dellanna; Michael Muenzberg; Ivo Abraham
Journal:  Intern Emerg Med       Date:  2011-05-18       Impact factor: 3.397

3.  Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia.

Authors:  H Kulaksiz; S G Gehrke; A Janetzko; D Rost; T Bruckner; B Kallinowski; W Stremmel
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 4.  Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.

Authors:  Robert Deicher; Walter H Hörl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 5.  Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulness.

Authors:  Yoram Yagil; Stephen Z Fadem; Kotagal S Kant; Udayan Bhatt; Mohammed Sika; Julia B Lewis; Dana Negoi
Journal:  Ther Adv Chronic Dis       Date:  2015-09       Impact factor: 5.091

6.  Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials.

Authors:  Michelle W Krause; Rasib Raja; Anil Agarwal; Marcia R Silver; Debra Scarlata; Angela Sciarra; Reshma Kewalramani
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

7.  Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia.

Authors:  Neval Duman; Abdullah Uyanik; Abdulkadir Unsal; Siren Sezer; Taner Camsari; Mustafa Cirit; Mehmet Emin Yilmaz; Bülent Altun; Murat Duranay; Alaattin Yildiz; Idris Sahin; Ayhan Dogukan; Sedat Ustundag; Ibrahim Karayaylali; Arzu Kahveci; Sukru Sindel; Ahmet Alper Kiykim; Yavuz Yenicerioglu; Ertugrul Akbas; Fatih Ozdener
Journal:  Clin Kidney J       Date:  2014-07-29

8.  Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study
.

Authors:  Gérard London; Johannes Mann; David Goldsmith; Christian Combe; Frank Dellanna; Philippe Zaoui; Nadja Hoebel; Andriy Krendyukov; Karen MacDonald; Ivo Abraham
Journal:  Clin Nephrol       Date:  2018-01       Impact factor: 0.975

9.  Toward confirmation of the safety and efficacy of methoxy polyethylene glycol-epoetin beta in anemia treatment in patients on hemodialysis: a Macedonian experience.

Authors:  Isidora Kacarska-Fotevska; Nadja Volckova; Katerina Ilievska; Doncho Donev
Journal:  Croat Med J       Date:  2019-10-31       Impact factor: 1.351

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.